| scholarly article | Q13442814 |
| P50 | author | Radu Iliescu | Q44192077 |
| Luciana A Campos | Q80033293 | ||
| P2093 | author name string | Jane F Reckelhoff | |
| Christian E Zaugg | |||
| Christoph Schumacher | |||
| Ovidiu Constantin Baltatu | |||
| Pat Louie | |||
| P2860 | cites work | Endothelin B receptor antagonism in the rat renal medulla reduces urine flow rate and sodium excretion | Q83895979 |
| Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 | ||
| Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure | Q28509867 | ||
| Renal medullary ETB receptors produce diuresis and natriuresis via NOS1 | Q28564721 | ||
| A novel potent vasoconstrictor peptide produced by vascular endothelial cells | Q29620540 | ||
| Differential regulation of central vasopressin receptors in transgenic rats with low brain angiotensinogen | Q33202520 | ||
| Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. | Q33675630 | ||
| Avosentan for overt diabetic nephropathy | Q33702404 | ||
| Relaxin is a potent renal vasodilator in conscious rats | Q33843076 | ||
| Relaxin: review of biology and potential role in treating heart failure | Q33873275 | ||
| BQ-788, a selective endothelin ET(B) receptor antagonist. | Q34133946 | ||
| Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials | Q34655367 | ||
| Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease | Q35077906 | ||
| Regulation of blood pressure and salt homeostasis by endothelin | Q35609851 | ||
| From biomarker strategies to biomarker activities and back | Q37636775 | ||
| Pharmacology of renal endothelin receptors | Q37926821 | ||
| Endothelin in chronic proteinuric kidney disease | Q37926840 | ||
| The endothelin system and endothelin receptor antagonists | Q37962118 | ||
| Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. | Q39305717 | ||
| Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct | Q41020851 | ||
| Endothelin as a regulator of cardiovascular function in health and disease | Q42463212 | ||
| Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. | Q44080388 | ||
| Relaxin-induced changes in renal function and RXFP1 receptor expression in the female rat. | Q44528656 | ||
| Renal autoregulation in midterm and late-pregnant rats | Q44911331 | ||
| Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial | Q44994661 | ||
| Relaxin-induced changes in renal sodium excretion in the anesthetized male rat. | Q45075430 | ||
| Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study | Q45259885 | ||
| Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects | Q46091583 | ||
| Extrarenal ETB plays a significant role in controlling cardiovascular responses to high dietary sodium in rats | Q46421402 | ||
| Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. | Q52953566 | ||
| Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor | Q72663940 | ||
| Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy | Q77141834 | ||
| Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention | Q79989204 | ||
| Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease | Q83489879 | ||
| P304 | page(s) | 103 | |
| P577 | publication date | 2012-04-18 | |
| P1433 | published in | Frontiers in Physiology | Q2434141 |
| P1476 | title | Antidiuretic effects of the endothelin receptor antagonist avosentan | |
| P478 | volume | 3 |
| Q39106330 | Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials |
| Q99210879 | Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet |
| Q38075029 | Emerging drugs for managing kidney disease in patients with diabetes. |
| Q36651592 | Nanomedicines for Endothelial Disorders |
| Q37621556 | Predictors of congestive heart failure after treatment with an endothelin receptor antagonist |
Search more.